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Abstract
Rationale: Population studies suggest improved sepsis outcomes
with statins, but the results of randomized controlled trials in patients
with sepsis and organ dysfunction in critical care settings have
broadly been negative. In vitrodata suggest that statinsmodulate age-
related neutrophil functions, improving neutrophil responses to
infection, but only in older patients and at high doses.
Objectives: To determine if high-dose simvastatin improves
neutrophil functions and is safe and tolerated in hospitalized older
adults with community-acquired pneumonia with sepsis (CAP1 S)
not admitted to critical care.
Methods:We conducted a randomized, double-blind, placebo-
controlled pilot study of simvastatin 80 mg or placebo for 7 days for
patients with CAP1 S aged 55 years or older admitted to a secondary
care hospital. The Day 4 primary endpoint was change in neutrophil
extracellular trap formation (NETosis). Day 4 secondary endpoints
included neutrophil chemotaxis, safety and tolerability, Sequential
Organ Failure Assessment score, mortality, readmission, and
markers of tissue degradation/inﬂammation.
Measurements and Main Results: Four days of simvastatin
adjuvant therapy in patients with CAP1 S was associated with
improvements in systemic neutrophil function (NETosis and
chemotaxis), a reduction in systemic neutrophil elastase burden, and
improved Sequential Organ Failure Assessment scores compared with
placebo.Aposthoc analysis demonstrated that simvastatin therapywas
associated with improved hospitalization-free survival compared with
placebo. Simvastatinwaswell tolerated in this elderly andmultimorbid
patient group with common coprescription of macrolide antibiotics.
Conclusions: This pilot study supports high-dose simvastatin as an
adjuvant therapy forCAP1 S inanolder andmilderdisease cohort than
assessed previously. A deﬁnitive multicenter study is now warranted in
this population to assess the likelihood of beneﬁt and harm.
Clinical trial registered with EudraCT (2012-00343-29).
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Pneumonia is the leading infectious cause of
death globally (1). Community-acquired
pneumonia (CAP) with sepsis (CAP1 S) is
common in the elderly and associated with
high mortality, and elderly survivors
experience increased long-term morbidity,
readmission, and a reduced quality of life
(2). Most CAP1 S cases are not caused by
multiresistant bacteria, even in vulnerable
adults (3). Given global concerns about
antibiotic usage, new strategies are needed
to improve patient outcomes.
Bacterial infections such as CAP
require a rapid but proportionate neutrophil
response, and neutrophils maintain an
exquisite, environment-dependent balance
between aggression or quiescence and
mortality and morbidity seen with either
inappropriately exaggerated or inhibited
responses (4). In sepsis, both heightened
and reduced neutrophil functions are
linked to mortality. For example, reduced
neutrophil extracellular trap formation
(NETosis) upon admission (potentially
representing an inadequate response) and
increased NETosis on Day 7 of the
admission (potentially representing
an overly aggressive, sustained
proinﬂammatory response) are associated
with poorer patient outcomes (5, 6).
Host age impacts neutrophil functions.
Neutrophils isolated in vitro from older
adults without an acute infection display
reduced neutrophil migratory accuracy (7),
phagocytosis (8), and NETosis (9),
although degranulation appears to be
increased (7). Our previous data suggest
that during infection in older adults, some
but not all functions are blunted further.
Migratory accuracy is reduced during
respiratory infections, which progresses to
migratory failure during sepsis, remaining
impaired 6 weeks after the initial infective
event (10). Phagocytosis of Escherichia coli
(11) and NETosis in response to PMA
(phorbol myristate acetate) (5) appears
preserved, and reactive oxygen species
generation may increase (12). A reduced
ability to target bacteria with enhanced
degranulation would potentially increase
bacterial invasion, local inﬂammation, and
bystander tissue damage, which is in
keeping with the higher burden of severe
sepsis and end-organ damage experienced
by the elderly (13).
There is great interest in using
3-hydroxy-3-methyl-glutaryl–coenzyme
A reductase inhibitors (“statins”) to improve
the immune response to infections, but
studies have shown discordant results.
In vitro and in a proof-of-concept clinical
trial, simvastatin improved the migratory
accuracy of neutrophils from older people
at therapeutically relevant concentrations
(10, 14). High-dose simvastatin increased
NETosis in vitro (15), whereas simvastatin
reduced NETosis in vivo in a murine model
(16). In observational studies and during
milder sepsis events, statins have been
associated with improved patient outcomes
(17). However, most studies of sepsis in
critical care units have shown no beneﬁt
(18), although a post hoc analysis identiﬁed
a group of responders (19). It seems likely
that the recipient, dose of statin, and timing
of the intervention are key. Of note,
simvastatin (C25H38O5) is a prodrug
activated by ﬁrst-pass hepatic metabolism
to a hydroxyacid metabolite (C25H40O6)
(20). Researchers in most in vitro studies do
not explicitly state whether they used the
prodrug but activated it or used the active
drug, and therefore discordant results may
represent off-target effects. Current human
studies suggest positive outcomes will be
limited to older patients receiving high-
dose statins early during a less severe
infection event (17, 21) or those receiving
statins before the infective insult (22, 23).
Statins have been prescribed in
critically ill patients (24), but some patients
experience serious side effects (25).
Concerns have been raised about
interactions between statins and
medications that inhibit the drug-
metabolizing enzyme cytochrome P450
3A4 (26), including clarithromycin,
commonly prescribed for patients with
CAP. However, a recent study found only a
small increase in the relative risk of adverse
events during coprescription (27).
We hypothesized that simvastatin
added to the standard treatment for older
patients with CAP1 S treated outside a
critical care setting would improve
neutrophil responses to infection (NETosis
and migratory accuracy) and would be well
tolerated and safe in this elderly population.
This proof-of-concept experimental
medicine study had three aims:
1. To determine if treatment with
simvastatin altered neutrophil function
in older patients with CAP1 S
2. To determine the safety and tolerability
of high-dose simvastatin in CAP1 S for
7 days
3. To ascertain if simvastatin had effects on
both clinical and laboratory outcomes
relevant to CAP1 S
Methods
Study Design
The trial schedule is shown in Figure 1.
Patients were eligible if they fulﬁlled the
criteria described in Table 1. The British
Thoracic Society guidelines for CAP require
patients to have at least three (of cough,
sputum production, breathlessness,
pleuritic chest pain, hemoptysis, fever, and
headache) signs that are consistent with
pneumonia on chest auscultation with a
chest X-ray of consolidative changes for
which there is no other clinical explanation
(28). Patients also had to meet the 2012
Surviving Sepsis Campaign guidelines (29).
This research was started before the Sepsis-
3 deﬁnitions (Third International
Consensus Deﬁnitions for Sepsis and Septic
Shock) of 2016. Sepsis and pneumonia
criteria had to be met within the same
24-hour period in patients enrolled within
48 hours of admission to the hospital.
At a Glance Commentary
Scientiﬁc Knowledge on the
Subject: Mortality of pneumonia-
associated sepsis in the elderly remains
high, with evidence of altered
neutrophil responses. There has been
interest in the adjuvant use of statins to
improve outcomes, but results of trials
in unselected patients with sepsis in
critical care units have been broadly
negative.
What This Study Adds to the Field:
This pilot randomized controlled
double-blind clinical trial demonstrates
simvastatin-associated improvements
in neutrophil functions and clinical
outcomes when used at a high dose in
elderly patients admitted to the
hospital with pneumonia-associated
sepsis who do not require critical care
unit support. These data suggest that
the patient population, dose, and
timing of the statin intervention are
crucial and that a larger multicenter
clinical trial is now needed to test the
potential for beneﬁt in this vulnerable
population.
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Eligible patients were included after
written informed consent or assent was
obtained from their personal legal
representatives or professional legal
representatives. Retrospective consent was
obtained when possible. The randomization
sequence was predetermined by Sharp
Clinical Services (UDG Healthcare plc) and
was designed to provide a 1:1 randomization
pattern. Standard treatments for pneumonia
(including antibiotics and ﬂuids) were
administered as directed by themedical team,
and these are listed in Table 1. Data for the
primary endpoint were collected within a
5-hour window after the fourth simvastatin
or placebo drug administration, and this is
referred to as “Day 4.” Throughout the
study, participants and researchers were
blinded to treatment until all study assays
were complete and 1-year survival data were
collected.
Endpoints
The primary outcome was change in
NETosis at Day 4 compared with Day 0.
The following were secondary outcomes:
1. Change in neutrophil migratory
accuracy at Day 4 compared with Day 0
2. Safety and tolerability of simvastatin
3. Change in extracellular matrix degradation
at Day 4 compared with Day 0
4. Mortality and readmissions at 30, 180,
and 365 days
5. Sequential Organ Failure Assessment
(SOFA) score
6. Critical care unit admissions
7. Critical care unit and hospital lengths
of stay
In detail, the laboratory comparisons
planned a priori were change in function
(Day 4 minus Day 0) and NETosis after
stimulation with formyl-methionyl-leucyl-
phenylalanine (fMLP), migration toward
IL8 (CXCL8), and measurement of systemic
NE (neutrophil elastase) activity as a
surrogate marker for extracellular matrix
degradation, as deﬁned in the statistical
analysis plan. The SOFA score is a well-
validated scoring system used to determine
the extent of organ failure. Six individual
organ systems are assessed (respiratory,
cardiovascular, liver, kidney, neurological,
and hematological), with a score of 0 to 4
given for each organ with a maximum score
of 24. Higher SOFA scores indicate a
greater burden of organ failure.
Exploratory and Post Hoc Analyses
Changes in inﬂammatory cytokines and
neutrophil/lymphocyte ratios (NLRs)
formed exploratory endpoints. Recently, the
Sepsis-3 (30) deﬁnitions were published. A
post hoc analysis of the key neutrophil
functions between the placebo and
simvastatin groups was performed,
classifying recruited patients by the
presence or absence of SOFA score greater
than or equal to 2 in the presence of
presumed/conﬁrmed infection.
In addition, a composite secondary
endpoint combining readmissions and
survival at 180 days and 1 year, termed
“hospitalization-free survival,” was
calculated as part of a post hoc analysis.
This patient-centered outcome (31, 32) was
included on the basis of discussion with
patient and public work groups (see online
supplement). Deaths were conﬁrmed at
180 and 365 days after enrollment.
Hospitalizations in the same period were
assessed through electronic patient records.
Time in days to the ﬁrst readmission or
death was compared between groups.
Neutrophil Studies
Full methods of all neutrophil studies are
detailed in the online supplement, including
validation of 100 nM fMLP to generate
NETosis in a CAP1 S population.
Neutrophils were isolated from whole blood
as described previously (33). The
neutrophils (.97% viable by exclusion
of trypan blue and .95% pure) were
resuspended in buffer (RPMI 1640
Admission
Identification and
recruitment of patients
admitted with CAP+S
Baseline neutrophil,
safety, and severity
assessments
Simvastatin
80mg PO OD
Randomization
Placebo PO OD Treatment
complete
Clinical
endpoints
Time 0 hours
(within 48 hours
from admission)
Primary Outcome endpoint
Day 4 treatment
from randomization
7 days from
randomization
12 months from
randomization
Neutrophil, safety, and
outcome assessments
Treatment
complete
Safety
Figure 1. The study schedule. Patients with community-acquired pneumonia and sepsis (CAP1S) were identified and recruited within 48 hours of
admission. Baseline information (clinical assessment, symptoms, blood samples for neutrophil isolation, clinical studies [including cholesterol, renal function,
liver function, a full blood count, clotting status, and creatine kinase], and inflammatory studies) was obtained just before randomization. After randomization,
patients were prescribed simvastatin 80 mg or placebo once daily for 7 days. Medications were dispensed by ward nursing staff, and tablet ingestion was
noted in an electronic prescribing log. On Day 4 (after the ingestion of the fourth tablet), clinical and safety data were collected alongside blood tests for
neutrophil studies, safety information, and inflammatory studies (as described above). These assessments were repeated 7 days after the ingestion of the first
tablet (after seven doses of the tablet) if patients remained as inpatients. Patients and their general practitioners were contacted, and electronic health records
were analyzed at 12 months after recruitment to gather data on readmission to the hospital and survival. OD=once daily; PO=by mouth.
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medium; Sigma-Aldrich) containing 0.15%
bovine serum albumin (Sigma-Aldrich).
NETosis. NETosis was induced in
freshly isolated CAP1 S neutrophils
stimulated with fMLP 100 nM to represent
a pathologically relevant stimulus and
25 nM PMA, used as a positive control, or
vehicle control (RPMI 1640 supplemented
with 2 nM L-glutamine, 100 U/ml
streptomycin, and 100 mg/ml penicillin)
(Sigma-Aldrich for all), as described
previously (9). Validation for fMLP as a
stimulus in patients with CAP1 S is
reported in the online supplement, and
these studies also informed power
calculations.
Neutrophil migration. Migration was
assessed using an Insall chamber (Weber
Scientiﬁc International Ltd.) as previously
described (34).
Neutrophil apoptosis. The percentage
of apoptotic neutrophils was determined
using the binding of annexin–ﬂuorescein
isothiocyanate (Thermo Fisher Scientiﬁc)
protein to the cell surface, as previously
described (9) and as presented in the online
supplement.
Neutrophil elastase activity. Aa-Val360
is an NE-speciﬁc ﬁbrinogen degradation
product and therefore a surrogate marker
of NE activity in vivo. Aa-Val360 was
measured in plasma using a highly
speciﬁc ELISA-based assay as described
previously (35).
White cell response and CRP. Differential
white cell count and CRP (C-reactive
protein) were measured by the National
Health Service laboratories and reported as
a standard clinical assessment. With these
measurements, changes in total white cell
count and NLR from Day 0 to Day 4 were
compared.
Systemic cytokines. Plasma cytokines
were measured using the Luminex
multianalyte assay kit (Bio-Techne) as per
the manufacturer’s instructions and
compared from Day 0 to Day 4.
Statistical Analysis
Statistical analyses were performed using
PASW Statistics version 18.0 software (SPSS
Inc.). Nonparametric tests were used
throughout. The assessments of neutrophil
functions (NETosis and chemotaxis) and
NE activity were performed by calculating
the change in these functions between Day 4
and baseline to provide a measure of the
treatment effect in each group. Power
calculations are provided below. All
statistical tests are listed for each
comparison and were two sided, with
P, 0.05 accepted as statistically signiﬁcant.
All clinical outcomes, including safety
monitoring, side effects, and adverse event
reporting, were based on intention to treat.
For SOFA scores and nonclinical outcomes,
the change from Day 0 to Day 4 was
compared in primary and secondary
endpoints, so those without data for Day 4
were excluded (see Figure 2). Reported
P values are not adjusted for multiple
comparisons, but all results are reported.
Power calculations. Our preliminary
studies suggested that mean NETosis from
systemic, isolated neutrophils from patients
with CAP upon admission was 7,500 AU
(SD, 2,432 AU). Eighteen patients in each
arm would be needed to change NETosis by
5,000 AU from Day 0 to Day 4 with a power
of 0.8 (P= 0.05), and 23 patients would be
needed in each arm for 0.9 power. In vitro
assays with neutrophils from patients with
CAP1 S suggested that simvastatin
incubation would reduce fMLP-induced
NETosis from a mean 5,298.8 AU (SD,
1,283 AU) to 4,173.6 AU (SD, 1,055 AU),
suggesting that 18 patients in each arm
would provide 0.8 power and 24 patients
in each arm would provide 0.9 power
(P= 0.05) (see Figure E1 in the online
supplement). Mean neutrophil migration in
older patients with CAP was suppressed to
0.8 mm/min (SD, 0.5 mm/min) versus 1
mm/min (SD, 0.4 mm/min) in age-matched
control neutrophils. Assuming that statin
treatment in vivo had a magnitude of effect
similar to that in vitro on elderly patient
neutrophils (187% accuracy), then 16
patients in each arm would be needed to
increase migratory accuracy by 0.7 mm/min
from Day 0 to Day 4 with a power of 0.8
(P= 0.05). To allow for dropouts, we aimed
to recruit at least 30 patients in each arm of
Table 1. Study Inclusion and Exclusion Criteria
Inclusion Criteria Exclusion Criteria
Age >55 yr Age ,55 yr
Patients with a diagnosis of
community-acquired pneumonia per
British Thoracic Society deﬁnition
More than 48 h from admission at time of
consent
Meet the criteria for sepsis on the basis
of the 2012 Surviving Sepsis Campaign
guidelines
Current or recent high-dose statin use within
1 mo (deﬁned as simvastatin .40 mg or
atorvastatin 20 mg or rosuvastatin 10 mg)
Known prior myositis or a family history of
muscular disorders
Creatine kinase .10 times upper limit of
normal*
Transaminases (ALT/AST) .8 times upper
limit of normal
Patients with severe renal impairment
(creatinine clearance ,30 ml/min) not
receiving renal replacement therapy
Patients currently receiving ongoing and
sustained treatment with any of the
following: itraconazole, ketoconazole,
posaconazole, voriconazole, telithromycin,
HIV protease inhibitors (e.g., nelﬁnavir,
boceprevir, and telaprevir), nefazodone,
cyclosporine, danazol, gemﬁbrozil, fusidic
acid, amiodarone, verapamil, diltiazem,
and ﬁbric acid derivatives (except
fenoﬁbrate)
Known HIV or hepatitis B or C virus infection
Contraindication to enteral drug
administration (either orally or nasogastric;
e.g., patients with mechanical bowel
obstruction)
Patient declines consent, relative or
advocate assent declined, or
professional consultee assent declined
Treatment withdrawal imminent within 24 h
Definition of abbreviations: ALT= alanine aminotransferase; AST=aspartate aminotransferase.
*Upper limit of normal of creatine kinase is 195 IU/L.
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this proof-of-concept study (therefore, a
minimum of 60 participants in total).
Results
This study was a single-center, randomized,
double-blind, placebo-controlled trial. The
initial protocol, registered with the
European Clinical Trials Database
(EudraCT identiﬁer 2012-003343-29),
required amendment, as published
elsewhere (36); however, a further
amendment was undertaken after the start
of recruitment. An abridged version of the
ﬁnal protocol is available in the online
supplement. The trial and all amendments
were approved by the Yorkshire and the
Humber Research Ethics Committee (REC
12/YH/0375), and patients with CAP1 S
were randomized to receive simvastatin
80 mg or placebo (both manufactured by
Sharp Clinical Services Ltd.) once daily for
7 days or until hospital discharge,
whichever was sooner. Patients were
followed for 12 months to assess
readmission rates and mortality. The
trial was ended once recruitment targets
were met.
In total, 62 patients were recruited
from one center (Queen Elizabeth
Hospital Birmingham, Birmingham, UK),
with clinical and safety data analyzed on
an intention-to-treat basis between
November 2013 and January 2016 and 1-
year follow-up completed in January 2017.
A modiﬁed Consolidated Standards of
Reporting Trials diagram is shown in
Figure 2. Table 2 describes patient
demographics. There were no differences
in baseline demographics between
patients in the intervention or placebo
group. Comorbidities are described in
Table E1.
Primary Outcome: Neutrophil
NETosis Is Reduced in Patients
Receiving Simvastatin
There were no differences in Day 0 fMLP-
associated NETosis between the two groups
(median [interquartile range (IQR)],
simvastatin 405.5 [232.1 to 883.8] AU vs.
placebo 488.8 [34.8 to 805.3] AU; P= 0.64
by Mann-Whitney U test). Simvastatin
treatment was associated with a signiﬁcant
change (reduction) in fMLP-induced
NETosis compared with placebo (median
79 did not meet criteria for CAP+S as per study protocol
32 were outside of 48-hour admission window
7 had treatment withdrawal planned
28 did not provide consent or assent not provided
13 had renal failure
14 were on contraindicated medications
1 had HIV
1 had Hep B
62 patients recruited to study with
baseline NET, migration, and safety
data
Primary endpoint neutrophil studies
25 NET
25 migration
25 safety data
Primary endpoint neutrophil studies
26 NET and migration
(2 declined blood test)
28 safety data
25 patients
Day 4
endpoint
28 patients
Day 4
endpoint
7 day neutrophil studies
10 NET, migration, and safety data
7 day neutrophil studies
17 NET, migration, and safety data
10 patients
7 day
endpoint
17 patients
7 day
endpoint
30 patients
12 month
endpoint
32 patients
12 month
endpoint
4 died
3 withdrawal
8 D/C
2 died
1 withdrawal
8 D/C
2 withdrew
3 D/C
1 withdrew
3 D/C
30 patients
randomized to
placebo
32 patients
randomized to
simvastatin
237 patients aged > 55 years with
admission diagnosis of CAP+S
screened
Figure 2. Modified Consolidated Standards of Reporting Trials diagram of trial endpoints. A total of 237 patients were screened with community-acquired
pneumonia and sepsis (CAP1S), but 28 did not provide consent or assent, 111 did not meet inclusion criteria, and 36 met exclusion criteria. Sixty-two
patients were recruited to the study, and all were followed for clinical endpoints at 12 months using an intention-to-treat analysis with consent even if they
withdrew from the study. Patients who did not complete simvastatin or placebo therapy to Day 4 endpoints or then to Day 7 endpoints because of study
withdrawal or hospital discharge were not included in neutrophil functional studies, because the study compared changes in function from baseline in a
paired analysis. D/C=discharged because of clinical recovery; NET=neutrophil extracellular trap.
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[IQR] change in NETosis [Day 42Day 0],
simvastatin 2230.0 [21,187.0 to 53.7] AU
vs. placebo 46.2 [2430.8 to 679.8] AU;
nominal P= 0.034 by Mann-Whitney U
test). See Figures 3 and E2 for NETosis
values on Day 0 and Day 4 for both groups.
There were no differences in PMA-
induced NETosis at baseline between the
two groups (median [IQR], 48,446.2
[37,616.7 to 55,489.0] AU for simvastatin
vs. 45,295.1 [37,971.2 to 52,841.6] AU for
placebo; P = 0.50 by Mann-Whitney U
test). There were no differences in the
changes in PMA-induced NETosis
between Day 4 and Day 0 between the two
groups (23,333.6 [211,332.5 to 8,091.9]
AU for simvastatin vs. 22,990.4
[210,322.8 to 7,790.3] AU for placebo;
P = 0.10 by Mann-Whitney U test). This
conﬁrmed that oral simvastatin reduced
NETosis after in vitro activation with a
pathologically relevant trigger, with studies
suggesting that NETosis can differ between
a physiological/pathological and a
nonphysiological/nonpathological (PMA)
trigger (37).
Neutrophil Migratory Accuracy
Improves in Patients Receiving
Simvastatin
There were no differences in Day
0 chemotaxis toward CXCL8 at baseline
between the two groups (median [IQR], 0.23
[20.01 to 0.74] mm/min for simvastatin vs.
0.24 [20.17 to 0.68] mm/min for placebo;
P= 0.52 by Mann-Whitney U test).
Simvastatin was associated with a greater
change (improvement) in migratory
accuracy than placebo (median [IQR]
change in chemotaxis [Day 42Day 0], 0.36
[20.43 to 0.86] mm/min for simvastatin vs.
20.04 [20.74 to 0.32] mm/min for placebo;
nominal P= 0.033 by Mann-Whitney U
test). See Figures 4 and E3 for chemotaxis
values on Day 0 and Day 4 for each group.
Neutrophil Apoptosis Does Not
Change with Simvastatin Treatment
There were no differences in the percentage
of early or late apoptotic cells on Day
0 or Day 4 between patients in either group
(see online supplement).
Systemic Neutrophil Elastase Activity
Falls in Patients Receiving
Simvastatin
Matched samples were available in 21 patients
in the simvastatin arm and 20 patients in the
placebo arm. Baseline characteristics did not
differ between this subcohort and the main
group. There were no differences in plasma
Aa360VAL at Day 0 between patients
receiving simvastatin or placebo (median
[IQR], 13.3 [9.6 to 14.8] nM for simvastatin
vs. 13.6 [9.7 to 17.0] nM for placebo; P=0.56
by Mann-Whitney U test). Simvastatin was
associated with a greater change in Aa360VAL
(reduction) between Day 4 and Day 0 than
placebo (median [IQR] change,22.55 [25.23
to 21.15] nM for simvastatin vs. 0.25 [22.13
to 1.916] nM for placebo; nominal P=0.001
by Mann-Whitney U test) (see Figures 5 and
E4 for actual data points on each day).
Simvastatin Is Not Associated with
Changes in the Neutrophil: NLR
The NLR is considered a biomarker of
adverse outcome in sepsis and may be
Table 2. Baseline Demographics of Patients in Placebo and Simvastatin Groups
Statin (n= 32) Placebo (n=30) P Value
Age, yr 78.1 (70–88) 83.8 (68–90) 0.283
Sex, M, n (%)* 19 (59%) 16 (53%) 0.616
Comorbidities, n (%) 0.215
0 0 (0%) 1 (3%)
1 16 (50%) 8 (27%)
2 8 (25%) 9 (30%)
3 or more 8 (25%) 12 (40%)
Severe sepsis, n (%)* 18 (56%) 18 (60%) 0.80
Sepsis-3 positive (27 of 62), n (%) 16 (50%) 11 (37%) 0.317
CURB-65 score 1 (1–2) 2 (1–2) 0.312
Patients receiving low-dose statins before
admission, n (%)*
5 (16%) 6 (20%) 0.745
C-reactive protein, mg/ml 139 (52–240) 156 (43–267) 0.809
Lactate, mmol/L 2.0 (1.2–2.8) 2.1 (1.3–2.9) 0.662
Creatinine, mmol/L 79.5 (66.5–105) 82.5 (70.5–92.3) 0.746
Creatine kinase, IU/L 85.5 (46.8–203) 62.5 (37–163) 0.129
Bilirubin, mmol/L 8 (6–14.3) 10 (6–16) 0.311
ALT, mmol/L 19 (13–24.8) 14.5 (13–27.3) 0.310
Total cholesterol, mmol/L 3 (2.5–3.8) 3.3 (2.6–4.5) 0.555
SOFA score 2 (1–3) 1 (0–3) 0.129
Antibiotics at admission, n (%)*
Cotreatment with amoxicillin/clavulanic
acid/clarithromycin
21 (66%) 17 (57%) 0.407
Piperacillin/tazobactam 8 (25%) 11 (37%) 0.642
Other 3 (9%) 2 (7%) 0.51
Definition of abbreviations: ALT= alanine aminotransferase; CURB-65 = confusion, urea, respiratory rate, blood pressure, and age 65 or over;
Sepsis-3= Third International Consensus Definitions for Sepsis and Septic Shock; SOFA=Sequential Organ Failure Assessment.
Sepsis-3 positive is defined as those patients who would be classified as having sepsis using the 2015 Sepsis-3 criteria (30). Values represent the median
(interquartile range) with P values derived from a Mann-Whitney U test, unless noted otherwise. See Table E1 for more details on comorbidities. Normal
ranges are as follows: C-reactive protein ,10 mg/ml, lactate 0–1 mmol/L, creatinine 45–110 mmol/L, creatine kinase 5–195 IU/L, bilirubin ,17 mmol/L,
ALT ,47 mmol/L, and total cholesterol ,6.2 mmol/L.
*Absolute values and P values derived from Fisher’s exact test.
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reduced by statin therapy (38). For both
the simvastatin- and placebo-treated
groups, there was a decrease in the NLR
from Day 0 to Day 4, assessed from full
blood counts (median [IQR] NLR, 10.3
[6.7 to 23.4] on Day 0 vs. 5.9 [3.4 to 8.2]
on Day 4 for simvastatin; nominal
P = 0.0001; 16.4 [11.0 to 24.7] on Day 0 vs.
7.5 [4.7 to 11.8] on Day 4 for placebo;
nominal P, 0.0001; Wilcoxon test
for both). There were no differences in
the change of the NLR between Day
0 and Day 4 between the placebo or
simvastatin group (P = 0.26 by Mann-
Whitney U test).
Simvastatin Was Not Associated with
Changes in CRP or Other Measured
Systemic Cytokines
There were no differences in Day 0 or Day 4
CRP or systemic cytokine concentrations
between the two groups. Furthermore, there
were no differences in the change between
Day 0 and Day 4 CRP or systemic cytokine
concentrations between the groups (see
online supplement).
Tolerability and Safety Data
Simvastatin 80 mg was well tolerated, with
no serious adverse reactions and only one
adverse reaction (myalgia). Biochemical
safety monitoring did not show any change
between Day 0 and Day 4 or between Day
0 and Day 7 on treatment, apart from
cholesterol, which was lower in patients
receiving simvastatin at Day 4 (see Table 3).
No patients met Hy’s law (drug-induced
liver injury, deﬁned as ALT [alanine
aminotransferase] elevation greater than
three times the upper limit of normal
[ULN] and/or total bilirubin elevation of
greater than two times the ULN [39]), and
no patients demonstrated rises in ALT
above the ULN. No patients demonstrated
a creatine kinase rise above the ULN.
Furthermore, no rises in either ALT or
creatine kinase were seen in patients
receiving simvastatin who were also
receiving clarithromycin. No patients
showed signs of rhabdomyolysis (symptoms
of muscle pain, muscle weakness, and
discolored urine or decreased urination in
the presence of high or increasing creatine
kinase and myoglobin concentrations in the
urine). Electronic hospital records
demonstrated good compliance with the
study drugs, with only three patients missing
one dose each of the study drug/placebo
(two for placebo and one for simvastatin).
Clinical Outcomes
SOFA scores were generally low, as expected
in this ward-based cohort of patients
with CAP. There was a greater change
(reduction) in SOFA score (Day 42Day 0;
median [IQR]) in patients receiving
simvastatin (22 [23 to 21]) than in those
receiving placebo (21 [22 to 0]) (nominal
P, 0.026 by Mann-Whitney U test; see
Figure 6). All patients treated with
simvastatin showed a reduction in SOFA
score, whereas three patients in the placebo
group showed an increase in SOFA score.
There were no differences in hospital
length of stay or readmissions between
groups. Placebo-treated patients had higher
mortality at 30, 180, and 365 days, but this
did not reach signiﬁcance using Fisher’s
exact test (see Table 4). In survivors, up to 1
year after discharge, there was no difference
in the time without readmission to the
hospital in the ﬁrst year (median [IQR],
365 [103 to 365] d for simvastatin; 172
[69 to 365] d for placebo; P= 0.33 by
Mann-Whitney U test).
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Figure 3. Change in neutrophil extracellular trap formation (NETosis) in patients with community-
acquired pneumonia and sepsis (Day 4 minus Day 0). Patients with community-acquired pneumonia
and sepsis received simvastatin 80 mg or placebo as well as standard medical treatment. Neutrophils
were stimulated with formyl-methionyl-leucyl-phenylalanine (100 nM), and after 3 hours, NET
formation was measured, both at Day 0 and at Day 4. Each dot represents one patient. NET data are
displayed as Day 4 formyl-methionyl-leucyl-phenylalanine–induced reduced NETosis minus Day 0
NETosis (therefore, the change in NETosis), measured in arbitrary units. The lines show the median
and interquartile range. Patients receiving simvastatin had a greater reduction in NETosis at Day 4
than patients receiving placebo (P=0.034 by Mann-Whitney U test).
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Figure 4. Change in chemotaxis in patients with community-acquired pneumonia and sepsis (Day 4
minus Day 0). Patients with community-acquired pneumonia and sepsis received simvastatin 80 mg
or placebo as well as standard medical treatment. Neutrophils migrated to CXCL8 (100 nM) isolated
both at Day 0 and at Day 4. Each dot represents one patient. Lines are median and interquartile
range. Chemotaxis data are measured in mm/min. Compared with placebo, simvastatin treatment
was associated with a greater change in the accuracy of neutrophil migration (improvement) from Day 0 to
Day 4 (P=0.03 by Mann-Whitney U test).
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Severity of Infection according to
Sepsis-3 Criteria
Patients’ severity of infection was stratiﬁed
in a post hoc analysis according to Sepsis-3
deﬁnitions, and neutrophil functions of
NETosis and chemotaxis were assessed. A
total of 27 (44%) patients met the Sepsis-3
deﬁnition (SOFA score >2), and the
simvastatin (n= 16) and placebo (n= 11)
groups showed no differences in patient
characteristics between the two groups (see
Table E2). None of the patients recruited to
the trial had septic shock, but two were
moved to critical care during their hospital
stay, neither of whom met the Sepsis-3
deﬁnition of septic shock.
There was no difference in NETosis at
Day 0 in those patients who met the
deﬁnition of sepsis according to the Sepsis-3
deﬁnition (Sepsis-3 +ve) and those who did
not meet the criteria for sepsis 3 (Sepsis-3
2ve) (fMLP, Sepsis-31ve 326.3 [2145.5 to
716.0] AU vs. Sepsis-3 2ve 488.8 [93.3 to
1,016.1] AU; P= 0.138 by Mann-Whitney
U test). We observed no difference in the
change of fMLP NETosis between Day
0 and Day 4 in Sepsis-3 1ve patients when
we compared those who received
simvastatin with those who received
placebo (median [IQR] change, 2215.0
[21,049.0 to 673.2] AU for simvastatin vs.
210.0 [2867.2 to 818.9] AU for placebo;
P= 0.601 by Mann-Whitney U test).
There was a trend toward reduced
chemotaxis on Day 0 in Sepsis-31ve versus
Sepsis-32ve patients (20.035 [20.2 to 0.4]
mm/min for Sepsis-3 1ve vs. 0.23 [20.3 to
0.8] mm/min for Sepsis-3 2ve; P= 0.07 by
Mann-Whitney U test). We observed no
difference in the change in chemotaxis
between Day 0 and Day 4 in Sepsis-3 1ve
patients when we compared those who
received simvastatin or placebo (median
[IQR] change, 0.43 [0.06 to 0.98] mm/min
for simvastatin; P= 0.15; 0.08 [20.7 to 0.8]
mm/min for placebo; P= 0.2; Wilcoxon test
for both).
Our a priori hypothesis was that
Sepsis-3 2ve patients would have a greater
neutrophil chemotactic response to
simvastatin. There was a trend in this
direction (Sepsis-3 2ve improvement
n= 12 [80%] vs. no improvement n= 3
[20%]; Sepsis-3 1ve improvement n= 4
[44.4%] vs. no improvement n= 5 [55.6%]),
but this did not reach signiﬁcance (P= 0.09
by two-tailed Fisher’s exact test).
Post Hoc Composite Clinical
Endpoint: Hospitalization-Free
Survival
Analysis of readmission and survival as a
composite endpoint demonstrated a
signiﬁcant increase in hospitalization-free
survival at both 180 days (odds ratio, 0.45;
95% conﬁdence interval, 0.22 to 0.93;
nominal P = 0.03) and 365 days (odds
ratio, 0.45; 95% conﬁdence interval, 0.22
to 0.90; nominal P = 0.03) for those
patients in the simvastatin group
compared with the placebo group (see
Figure 7).
Discussion
To our knowledge, this proof-of-concept
study provides the ﬁrst report of a
therapeutic intervention impacting
neutrophil functions and clinical
endpoints in older patients with CAP1 S.
At Day 4, simvastatin was associated with
reductions in neutrophil NETosis (after
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Figure 5. Change in systemic neutrophil elastase activity in patients with community-acquired
pneumonia and sepsis (Day 4 minus Day 0). Patients with community-acquired pneumonia and
sepsis received simvastatin 80 mg or placebo as well as standard medical treatment. Plasma
Aa360VAL was measured. Each dot represents one patient. The lines are the median and
interquartile range. Compared with placebo, simvastatin treatment was associated with a
significant reduction in systemic neutrophil elastase activity (Day 4 minus Day 0; P= 0.001 by
Mann-Whitney U test).
Table 3. Biochemical Safety Data
Day 4 Values Day 7 Values
Statin (n= 32) Placebo (n= 30) P Value Statin (n= 17) Placebo (n=10) P Value
C-reactive protein, mg/ml 86 (35–198) 59 (27–116) 0.248 55 (11–82) 26 (11–43) 0.561
Creatinine, mmol/L 65 (62–95) 66 (50–83) 0.552 66 (57–83) 68 (54–85) 0.975
Creatine kinase, IU/L 90 (57–132) 41 (28–116) 0.061 42 (33–130) 59 (22–91) 0.187
Bilirubin, mmol/L 7 (6–10) 8 (6–14.5) 0.618 8 (5–12) 7 (5–11) 0.716
ALT, mmol/L 22 (16–31.5) 21.5 (14–34.3) 0.404 29.5 (16–59) 25 (17–38) 0.662
Total cholesterol, mmol/L 3.1 (2.4–3.7) 4.0 (3.6–4.5) 0.006 N/A N/A
Definition of abbreviations: ALT= alanine aminotransferase; N/A=not available.
Data were analyzed on an intention-to-treat basis. Values are represented as median (interquartile range) with P values derived by Mann-Whitney
U test. Normal ranges are as follows: C-reactive protein ,10 mg/ml, lactate 0–1 mmol/L, creatinine 45–110 mmol/L, creatine kinase 5–195 IU/L, bilirubin
,17 mmol/L, ALT ,47 mmol/L, and total cholesterol ,6.2 mmol/L. Cholesterol was measured on Day 0 and Day 4 only.
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physiological stimulation) and systemic
NE activity, improved neutrophil
migrational accuracy, and a small
reduction in SOFA score. Furthermore,
high-dose simvastatin was safe and
tolerated with the coprescription of
clarithromycin. Although mortality
and time to readmission or readmission
rates were not different between groups,
a post hoc analysis suggested that
simvastatin treatment was associated
with increased hospitalization-free
survival, an endpoint highlighted as
important by patients and included in
clinical trials (40).
Pneumonia hospitalizations are
predicted to double by 2040 (41), and the
World Health Organization has called for
new strategies for treating infectious
diseases (42). This proof-of-concept study
suggests that modifying neutrophil
function may improve outcomes during
acute infection, but it also highlights
the complex, stimulus-speciﬁc, and
dynamic nature of neutrophil responses
in sepsis.
In the present study, we interpret a
reduction in NETosis and NE activity
and an improvement in neutrophil
migratory accuracy at Day 4 as positive,
antiinﬂammatory events. The optimal
neutrophil response to infection should be
proportionate to the degree of threat and
will vary during the course of the illness,
from infection onset (when responses
should be proinﬂammatory and
bactericidal) to recovery (when these
proinﬂammatory responses should
diminish). Sustained NETosis is associated
with endovascular damage and
coagulopathy in human and murine
sepsis (43, 44). Reduced migratory
accuracy has been associated
with poor patient outcomes and increased
tissue damage due to obligate proteolysis
(34, 45). Fibrinogen degradation is a
marker of systemic NE activity, and NE
has pleiotropic proinﬂammatory effects
that may drive tissue injury (46).
CAP bacterial eradication is commonly
seen within approximately 3 days with
appropriate treatment (47, 48), and negative
outcomes are rarely associated with
antibiotic failure but are associated with
dysregulated immune responses. We
propose that inappropriately sustained
proinﬂammatory responses at Day 4 should
be considered pathological. There is some
evidence to support this. For example,
sustained NETosis is implicated in end
organ damage in sepsis (49). In this study,
we aimed to normalize functions to their
“optimal” state at Day 4, which we assumed
to be a less inﬂammatory state than at
Day 0.
The pleiotropic effects of statins have
led to studies in sepsis and acute
respiratory distress syndrome, but
evidence of efﬁcacy is controversial.
In most cases, results of phase 3 trials
have been negative in patients recruited
from critical care units (50), although
recently a group of patients with
“hyperinﬂammatory” acute respiratory
distress syndrome showed beneﬁt (19),
supporting our data that simvastatin
has an “antiinﬂammatory” effect in vivo.
Most previous studies included a wide
range of patients and diseases, and many
used “low” statin doses. We and others
have described how the patient group
(older), severity of the host insult
(milder), dose of statin (higher), and
timing of the intervention (early) are
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Figure 6. Change in Sequential Organ Failure Assessment (SOFA) score in patients with
community-acquired pneumonia and sepsis from Day 0 to Day 4. Patients with community-
acquired pneumonia and sepsis received simvastatin 80 mg or placebo as well as standard
medical treatment. SOFA score was calculated. Each dot represents one patient. The lines are
the median and interquartile range. Compared with placebo, simvastatin treatment was
associated with a greater change (reduction) in SOFA score (Day 4 minus Day 0; P = 0.026 by
Mann-Whitney U test).
Table 4. Clinical Outcomes
Simvastatin (n=32) Placebo (n=30) P Value
Change in SOFA score, median (IQR) 21.5 (23 to 21) 21 (22 to 0) 0.040
Length of stay, d, median (IQR) 9.5 (5 to 21) 9 (6 to 14) 0.578
Number of patients readmitted within 180 d, n (%) 9 (28%) 13 (43%) 0.290
Number of patients readmitted within 365 d, n (%) 11 (34%) 13 (43%) 0.601
30-d mortality, n (%) 2 (6%) 6 (20%) 0.141
Cumulative 90-d mortality, n (%) 4 (13%) 8 (27%) 0.206
Cumulative 180-d mortality, n (%) 5 (16%) 10 (33%) 0.141
Cumulative 1-yr mortality, n (%) 7 (22%) 13 (43%) 0.103
Definition of abbreviations: IQR= interquartile range; SOFA=Sequential Organ Failure Assessment.
Length of stay, readmission (over 365 d), and all-cause mortality for all patients were analyzed on an intention-to-treat basis. Mortality is all-cause and
cumulative, with differences assessed using Fisher’s exact test. Length of stay is expressed as the median in days with IQR, and differences were
compared using the Mann-Whitney U test.
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likely to impact the effectiveness of the
therapy (21). Concordantly, a recent
meta-analysis (51) suggested that statins
reduced mortality after nonsevere
pneumonia but not after severe
pneumonia. Our study did not identify
changes in systemic proinﬂammatory
mediators but was not powered for this
endpoint (which was considered
exploratory); therefore, further studies
could assess whether a greater statin
response is seen in patients with a more
proinﬂammatory systemic readout, as
recently reported (19).
Our patient cohort was elderly and
had signiﬁcant medical comorbidities,
but these were well matched between
groups. The Kaplan-Meier curves for
hospitalization-free survival diverged from
approximately 20 days after enrollment,
suggesting that simvastatin had a long-
term beneﬁcial effect, but the mechanism
for this is unclear, and further studies are
needed to explore this. However, statins
are known to have multiple epigenetic
effects on a wide number of cell types
even after short-term exposure (52), and
statins can affect immune cell signaling,
gene transcription, epigenetic
modiﬁcation, and metabolism in both
mature and immature progenitor cells
(53). It is possible that the long-term
effects of a short course of simvastatin
might be through neutrophil progenitors,
but this is speculation.
The present study has important
limitations. The study was not powered for
any of the clinical endpoints included, so
these results must be interpreted with
caution. We could not explore differences
in patients’ responses to simvastatin,
which might inform who would gain the
most clinical beneﬁt from adjuvant
therapy, and further trials should focus on
this. Although simvastatin was considered
safe and well tolerated in this group, the
study was not powered to assess
differences in creatine kinase or liver
dysfunction, and a larger study is needed
to assess safety (as well as efﬁcacy)
further. This study assessed ALT only for
liver dysfunction, but this has been found
to be sufﬁcient in a recent study of statins
(54). Not all neutrophil functions could
be studied, nor did we assess the
mechanism of effect of simvastatin on
neutrophil functions. Furthermore, the
effect of simvastatin on other immune
cells requires clariﬁcation. The
understanding of neutrophil responses,
including NETosis, is evolving. In many
studies, PMA is used as the gold standard
for maximal NET generation; however, we
chose fMLP because this represents a
physiologically relevant stimulus. We
demonstrate that fMLP is sufﬁcient to
cause NETosis in systemic neutrophils
from the inﬂammatory environment of
sepsis, and there are studies highlighting
important differences in NETosis
triggered by biologically relevant stimuli
from that triggered by PMA (37). The
assay for NETosis only included live-cell
imaging in a proportion of patients, and
therefore our indirectly measured assay,
although included in many publications,
should be considered a limitation. Also,
the change in NETosis seen in this study
between Day 0 and Day 4 was less
than predicted in our a priori power
calculations. It is difﬁcult to judge what
the minimally important effect size is for
a cellular function, and this may be
dependent on how much NETosis is
required to contain bacteria in a speciﬁc
setting. However, although the actual
change in NETosis was relatively small,
it is notable that a number of cellular
functions seemed to change in a manner
that might be associated with less tissue
damage to the host at Day 4 (improved
neutrophil directional migration, a
reduced signal of proteinase activity,
and reduced NETosis at Day 4).
Despite these limitations, this trial is of
importance. This study highlights that it is
possible to conduct a randomized controlled
trial in elderly and acutely unwell patients
outside a critical care setting. The trial also is
the ﬁrst to demonstrate improvements in
neutrophil functions that are impeded with
age and infection and to link these to clinical
beneﬁt. The study provides further clarity
on the potential role of simvastatin during
infections, including which patients (older),
when (early and mild), at what dose (high),
and for how long (7 d). It also provides
reassurance that high-dose simvastatin is
safe. There is now a pressing need for a
multicenter trial in a ward-based cohort of
patients with pneumonia and to consider a
similar approach in other infections. These
trials should clarify both efﬁcacy (using both
mortality and readmission, which appeared
of particular importance to patients) and
risk, and they should also try to determine
whether the effect on neutrophil function is
indeed a critical function of response or
whether other cellular mechanisms are
equally important. n
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Figure 7. Kaplan-Meier curves for hospitalization-free survival at 365 days in an intention-to-treat
analysis. The black line represents the simvastatin group, and the gray line represents patients who
received placebo. The 365-day hospitalization-free survival rate demonstrates an odds ratio of 0.45
(95% confidence interval, 0.22–0.90; P=0.03).
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